nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MET—uterine cancer	0.22	0.515	CbGaD
Crizotinib—IGF1R—uterine cancer	0.208	0.485	CbGaD
Crizotinib—AURKA—Epirubicin—uterine cancer	0.143	0.541	CbGbCtD
Crizotinib—AURKA—Doxorubicin—uterine cancer	0.076	0.287	CbGbCtD
Crizotinib—CYP3A5—Progesterone—uterine cancer	0.0104	0.0393	CbGbCtD
Crizotinib—ABCB1—Progesterone—uterine cancer	0.00676	0.0256	CbGbCtD
Crizotinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.00612	0.0231	CbGbCtD
Crizotinib—ABCB1—Dactinomycin—uterine cancer	0.00536	0.0203	CbGbCtD
Crizotinib—CYP3A5—Etoposide—uterine cancer	0.00465	0.0176	CbGbCtD
Crizotinib—CYP3A4—Progesterone—uterine cancer	0.00405	0.0153	CbGbCtD
Crizotinib—ABCB1—Etoposide—uterine cancer	0.00303	0.0114	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—uterine cancer	0.00206	0.00781	CbGbCtD
Crizotinib—CYP3A4—Etoposide—uterine cancer	0.00181	0.00686	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—uterine cancer	0.00124	0.00468	CbGbCtD
Crizotinib—CASK—Teniposide—Etoposide—uterine cancer	0.000333	0.117	CbGdCrCtD
Crizotinib—Neuropathy—Etoposide—uterine cancer	0.000314	0.00424	CcSEcCtD
Crizotinib—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.000314	0.00424	CcSEcCtD
Crizotinib—Febrile neutropenia—Epirubicin—uterine cancer	0.000312	0.00421	CcSEcCtD
Crizotinib—Transaminases increased—Epirubicin—uterine cancer	0.000308	0.00416	CcSEcCtD
Crizotinib—Eye disorder—Progesterone—uterine cancer	0.000307	0.00415	CcSEcCtD
Crizotinib—Cardiac disorder—Progesterone—uterine cancer	0.000305	0.00412	CcSEcCtD
Crizotinib—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	0.000303	0.00409	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Dactinomycin—uterine cancer	0.000302	0.00408	CcSEcCtD
Crizotinib—Hypophosphataemia—Doxorubicin—uterine cancer	0.000299	0.00403	CcSEcCtD
Crizotinib—Mediastinal disorder—Progesterone—uterine cancer	0.000296	0.004	CcSEcCtD
Crizotinib—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.000294	0.00397	CcSEcCtD
Crizotinib—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.000293	0.00396	CcSEcCtD
Crizotinib—Generalised oedema—Doxorubicin—uterine cancer	0.000292	0.00394	CcSEcCtD
Crizotinib—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.000292	0.00394	CcSEcCtD
Crizotinib—Sepsis—Etoposide—uterine cancer	0.00029	0.00392	CcSEcCtD
Crizotinib—Febrile neutropenia—Doxorubicin—uterine cancer	0.000288	0.0039	CcSEcCtD
Crizotinib—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.000287	0.00387	CcSEcCtD
Crizotinib—Malnutrition—Progesterone—uterine cancer	0.000286	0.00386	CcSEcCtD
Crizotinib—Transaminases increased—Doxorubicin—uterine cancer	0.000285	0.00385	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Etoposide—uterine cancer	0.000279	0.00377	CcSEcCtD
Crizotinib—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.000278	0.00376	CcSEcCtD
Crizotinib—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.000276	0.00373	CcSEcCtD
Crizotinib—Neutropenia—Dactinomycin—uterine cancer	0.000271	0.00366	CcSEcCtD
Crizotinib—Neuralgia—Epirubicin—uterine cancer	0.00027	0.00365	CcSEcCtD
Crizotinib—Burning sensation—Epirubicin—uterine cancer	0.00027	0.00365	CcSEcCtD
Crizotinib—Vision blurred—Progesterone—uterine cancer	0.000269	0.00364	CcSEcCtD
Crizotinib—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000268	0.00362	CcSEcCtD
Crizotinib—Anaemia—Progesterone—uterine cancer	0.000264	0.00357	CcSEcCtD
Crizotinib—Pneumonia—Dactinomycin—uterine cancer	0.00026	0.00351	CcSEcCtD
Crizotinib—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000259	0.0035	CcSEcCtD
Crizotinib—Syncope—Progesterone—uterine cancer	0.000256	0.00346	CcSEcCtD
Crizotinib—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.000254	0.00343	CcSEcCtD
Crizotinib—Loss of consciousness—Progesterone—uterine cancer	0.000251	0.00339	CcSEcCtD
Crizotinib—Neuralgia—Doxorubicin—uterine cancer	0.00025	0.00337	CcSEcCtD
Crizotinib—Burning sensation—Doxorubicin—uterine cancer	0.00025	0.00337	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000242	0.00327	CcSEcCtD
Crizotinib—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.000239	0.00324	CcSEcCtD
Crizotinib—Abscess—Epirubicin—uterine cancer	0.000237	0.0032	CcSEcCtD
Crizotinib—Oedema—Progesterone—uterine cancer	0.000233	0.00315	CcSEcCtD
Crizotinib—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.000232	0.00314	CcSEcCtD
Crizotinib—Infection—Progesterone—uterine cancer	0.000232	0.00313	CcSEcCtD
Crizotinib—Shock—Progesterone—uterine cancer	0.00023	0.0031	CcSEcCtD
Crizotinib—Nervous system disorder—Progesterone—uterine cancer	0.000229	0.00309	CcSEcCtD
Crizotinib—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.000228	0.00308	CcSEcCtD
Crizotinib—Skin disorder—Progesterone—uterine cancer	0.000227	0.00306	CcSEcCtD
Crizotinib—Abscess—Doxorubicin—uterine cancer	0.000219	0.00296	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000219	0.00296	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Etoposide—uterine cancer	0.000214	0.00289	CcSEcCtD
Crizotinib—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000211	0.00286	CcSEcCtD
Crizotinib—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00021	0.00284	CcSEcCtD
Crizotinib—Paraesthesia—Progesterone—uterine cancer	0.00021	0.00283	CcSEcCtD
Crizotinib—Dyspnoea—Progesterone—uterine cancer	0.000208	0.00281	CcSEcCtD
Crizotinib—Shock—Medroxyprogesterone Acetate—uterine cancer	0.000208	0.00281	CcSEcCtD
Crizotinib—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000207	0.0028	CcSEcCtD
Crizotinib—Dyspepsia—Progesterone—uterine cancer	0.000205	0.00277	CcSEcCtD
Crizotinib—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000205	0.00277	CcSEcCtD
Crizotinib—Decreased appetite—Progesterone—uterine cancer	0.000203	0.00274	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Progesterone—uterine cancer	0.000201	0.00272	CcSEcCtD
Crizotinib—Fatigue—Progesterone—uterine cancer	0.000201	0.00272	CcSEcCtD
Crizotinib—Constipation—Progesterone—uterine cancer	0.0002	0.0027	CcSEcCtD
Crizotinib—Neutropenia—Etoposide—uterine cancer	0.000196	0.00265	CcSEcCtD
Crizotinib—Gait disturbance—Epirubicin—uterine cancer	0.000192	0.0026	CcSEcCtD
Crizotinib—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00019	0.00257	CcSEcCtD
Crizotinib—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000189	0.00255	CcSEcCtD
Crizotinib—Pneumonia—Etoposide—uterine cancer	0.000188	0.00254	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Epirubicin—uterine cancer	0.000188	0.00253	CcSEcCtD
Crizotinib—Pulmonary embolism—Epirubicin—uterine cancer	0.000188	0.00253	CcSEcCtD
Crizotinib—Infestation NOS—Etoposide—uterine cancer	0.000187	0.00253	CcSEcCtD
Crizotinib—Infestation—Etoposide—uterine cancer	0.000187	0.00253	CcSEcCtD
Crizotinib—Anaemia—Dactinomycin—uterine cancer	0.000187	0.00252	CcSEcCtD
Crizotinib—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000186	0.00251	CcSEcCtD
Crizotinib—Body temperature increased—Progesterone—uterine cancer	0.000184	0.00249	CcSEcCtD
Crizotinib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000184	0.00248	CcSEcCtD
Crizotinib—Neuropathy peripheral—Etoposide—uterine cancer	0.000183	0.00248	CcSEcCtD
Crizotinib—AXL—endometrium—uterine cancer	0.000183	0.00183	CbGeAlD
Crizotinib—JAK2—decidua—uterine cancer	0.000183	0.00183	CbGeAlD
Crizotinib—TESK1—vagina—uterine cancer	0.000183	0.00183	CbGeAlD
Crizotinib—IRAK1—mammalian vulva—uterine cancer	0.000183	0.00183	CbGeAlD
Crizotinib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000183	0.00247	CcSEcCtD
Crizotinib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000182	0.00246	CcSEcCtD
Crizotinib—EPHB4—renal system—uterine cancer	0.000181	0.00181	CbGeAlD
Crizotinib—MAP3K2—uterus—uterine cancer	0.000181	0.00181	CbGeAlD
Crizotinib—EPHA2—decidua—uterine cancer	0.000181	0.00181	CbGeAlD
Crizotinib—Leukopenia—Dactinomycin—uterine cancer	0.000181	0.00244	CcSEcCtD
Crizotinib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000181	0.00244	CcSEcCtD
Crizotinib—DSTYK—lymph node—uterine cancer	0.000181	0.0018	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—uterine cancer	0.00018	0.0018	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—uterine cancer	0.00018	0.0018	CbGeAlD
Crizotinib—JAK2—renal system—uterine cancer	0.00018	0.0018	CbGeAlD
Crizotinib—BMP2K—female reproductive system—uterine cancer	0.000179	0.00179	CbGeAlD
Crizotinib—RPS6KB1—mammalian vulva—uterine cancer	0.000179	0.00179	CbGeAlD
Crizotinib—MERTK—female gonad—uterine cancer	0.000179	0.00179	CbGeAlD
Crizotinib—BLK—lymph node—uterine cancer	0.000178	0.00178	CbGeAlD
Crizotinib—LCK—mammalian vulva—uterine cancer	0.000178	0.00178	CbGeAlD
Crizotinib—FGR—mammalian vulva—uterine cancer	0.000178	0.00178	CbGeAlD
Crizotinib—Fluid retention—Epirubicin—uterine cancer	0.000178	0.00241	CcSEcCtD
Crizotinib—Gait disturbance—Doxorubicin—uterine cancer	0.000178	0.0024	CcSEcCtD
Crizotinib—MERTK—vagina—uterine cancer	0.000178	0.00178	CbGeAlD
Crizotinib—PTK2—uterus—uterine cancer	0.000177	0.00177	CbGeAlD
Crizotinib—AXL—mammalian vulva—uterine cancer	0.000177	0.00177	CbGeAlD
Crizotinib—EPHB6—uterine cervix—uterine cancer	0.000177	0.00177	CbGeAlD
Crizotinib—Hepatobiliary disease—Etoposide—uterine cancer	0.000177	0.00239	CcSEcCtD
Crizotinib—MAP3K3—decidua—uterine cancer	0.000177	0.00177	CbGeAlD
Crizotinib—MAP4K5—decidua—uterine cancer	0.000177	0.00177	CbGeAlD
Crizotinib—TEK—decidua—uterine cancer	0.000177	0.00177	CbGeAlD
Crizotinib—SLK—endometrium—uterine cancer	0.000177	0.00176	CbGeAlD
Crizotinib—LTK—lymph node—uterine cancer	0.000176	0.00176	CbGeAlD
Crizotinib—CASK—lymph node—uterine cancer	0.000176	0.00176	CbGeAlD
Crizotinib—TYK2—uterus—uterine cancer	0.000176	0.00176	CbGeAlD
Crizotinib—Neuropathy—Epirubicin—uterine cancer	0.000176	0.00238	CcSEcCtD
Crizotinib—EPHB4—endometrium—uterine cancer	0.000175	0.00175	CbGeAlD
Crizotinib—LIMK2—female gonad—uterine cancer	0.000175	0.00175	CbGeAlD
Crizotinib—NUAK2—female gonad—uterine cancer	0.000174	0.00174	CbGeAlD
Crizotinib—JAK2—endometrium—uterine cancer	0.000174	0.00174	CbGeAlD
Crizotinib—LIMK2—vagina—uterine cancer	0.000174	0.00174	CbGeAlD
Crizotinib—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.000174	0.00234	CcSEcCtD
Crizotinib—Pulmonary embolism—Doxorubicin—uterine cancer	0.000174	0.00234	CcSEcCtD
Crizotinib—TEK—renal system—uterine cancer	0.000173	0.00173	CbGeAlD
Crizotinib—NUAK2—vagina—uterine cancer	0.000173	0.00173	CbGeAlD
Crizotinib—PTK2B—female reproductive system—uterine cancer	0.000173	0.00173	CbGeAlD
Crizotinib—ACVR1—female gonad—uterine cancer	0.000173	0.00173	CbGeAlD
Crizotinib—MAP3K12—female gonad—uterine cancer	0.000173	0.00173	CbGeAlD
Crizotinib—FLT3—female gonad—uterine cancer	0.000173	0.00173	CbGeAlD
Crizotinib—MAP3K12—vagina—uterine cancer	0.000172	0.00172	CbGeAlD
Crizotinib—ACVR1—vagina—uterine cancer	0.000172	0.00172	CbGeAlD
Crizotinib—EPHA2—endometrium—uterine cancer	0.000172	0.00172	CbGeAlD
Crizotinib—RIPK2—female reproductive system—uterine cancer	0.000172	0.00172	CbGeAlD
Crizotinib—YES1—uterine cervix—uterine cancer	0.000171	0.00171	CbGeAlD
Crizotinib—MAPK7—lymph node—uterine cancer	0.000171	0.00171	CbGeAlD
Crizotinib—TXK—lymph node—uterine cancer	0.000171	0.00171	CbGeAlD
Crizotinib—SLK—mammalian vulva—uterine cancer	0.000171	0.00171	CbGeAlD
Crizotinib—STK10—uterine cervix—uterine cancer	0.00017	0.0017	CbGeAlD
Crizotinib—LCK—uterus—uterine cancer	0.00017	0.0017	CbGeAlD
Crizotinib—STK35—female gonad—uterine cancer	0.00017	0.0017	CbGeAlD
Crizotinib—EPHB4—mammalian vulva—uterine cancer	0.00017	0.00169	CbGeAlD
Crizotinib—FES—lymph node—uterine cancer	0.000169	0.00169	CbGeAlD
Crizotinib—TAOK3—uterine cervix—uterine cancer	0.000169	0.00169	CbGeAlD
Crizotinib—AXL—uterus—uterine cancer	0.000169	0.00169	CbGeAlD
Crizotinib—EPHB6—decidua—uterine cancer	0.000169	0.00169	CbGeAlD
Crizotinib—STK35—vagina—uterine cancer	0.000169	0.00168	CbGeAlD
Crizotinib—JAK2—mammalian vulva—uterine cancer	0.000168	0.00168	CbGeAlD
Crizotinib—MAP3K3—endometrium—uterine cancer	0.000168	0.00168	CbGeAlD
Crizotinib—MAP4K5—endometrium—uterine cancer	0.000168	0.00168	CbGeAlD
Crizotinib—TEK—endometrium—uterine cancer	0.000168	0.00168	CbGeAlD
Crizotinib—Asthenia—Progesterone—uterine cancer	0.000167	0.00226	CcSEcCtD
Crizotinib—Hypoaesthesia—Etoposide—uterine cancer	0.000167	0.00226	CcSEcCtD
Crizotinib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000167	0.00226	CcSEcCtD
Crizotinib—YES1—smooth muscle tissue—uterine cancer	0.000166	0.00166	CbGeAlD
Crizotinib—EPHA2—mammalian vulva—uterine cancer	0.000166	0.00166	CbGeAlD
Crizotinib—SRC—epithelium—uterine cancer	0.000166	0.00166	CbGeAlD
Crizotinib—EPHA4—female reproductive system—uterine cancer	0.000166	0.00166	CbGeAlD
Crizotinib—Urinary tract disorder—Etoposide—uterine cancer	0.000166	0.00224	CcSEcCtD
Crizotinib—ABL2—female gonad—uterine cancer	0.000165	0.00165	CbGeAlD
Crizotinib—Oedema—Dactinomycin—uterine cancer	0.000165	0.00223	CcSEcCtD
Crizotinib—SRC—uterine cervix—uterine cancer	0.000165	0.00165	CbGeAlD
Crizotinib—Fluid retention—Doxorubicin—uterine cancer	0.000165	0.00223	CcSEcCtD
Crizotinib—Urethral disorder—Etoposide—uterine cancer	0.000165	0.00223	CcSEcCtD
Crizotinib—PLK4—Teniposide—Etoposide—uterine cancer	0.000164	0.058	CbGdCrCtD
Crizotinib—ABL2—vagina—uterine cancer	0.000164	0.00164	CbGeAlD
Crizotinib—Infection—Dactinomycin—uterine cancer	0.000164	0.00221	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—uterine cancer	0.000163	0.0576	CbGdCrCtD
Crizotinib—BMP2K—female gonad—uterine cancer	0.000163	0.00163	CbGeAlD
Crizotinib—YES1—decidua—uterine cancer	0.000163	0.00163	CbGeAlD
Crizotinib—Neuropathy—Doxorubicin—uterine cancer	0.000163	0.0022	CcSEcCtD
Crizotinib—MAP3K2—female reproductive system—uterine cancer	0.000163	0.00163	CbGeAlD
Crizotinib—Sepsis—Epirubicin—uterine cancer	0.000163	0.0022	CcSEcCtD
Crizotinib—SLK—uterus—uterine cancer	0.000163	0.00163	CbGeAlD
Crizotinib—MAP4K5—mammalian vulva—uterine cancer	0.000162	0.00162	CbGeAlD
Crizotinib—MAP3K3—mammalian vulva—uterine cancer	0.000162	0.00162	CbGeAlD
Crizotinib—BMP2K—vagina—uterine cancer	0.000162	0.00162	CbGeAlD
Crizotinib—STK10—decidua—uterine cancer	0.000162	0.00162	CbGeAlD
Crizotinib—EPHB4—uterus—uterine cancer	0.000161	0.00161	CbGeAlD
Crizotinib—TAOK3—decidua—uterine cancer	0.000161	0.00161	CbGeAlD
Crizotinib—EPHB6—endometrium—uterine cancer	0.00016	0.0016	CbGeAlD
Crizotinib—YES1—renal system—uterine cancer	0.00016	0.0016	CbGeAlD
Crizotinib—SRC—smooth muscle tissue—uterine cancer	0.00016	0.0016	CbGeAlD
Crizotinib—MET—lymph node—uterine cancer	0.00016	0.0016	CbGeAlD
Crizotinib—Diarrhoea—Progesterone—uterine cancer	0.00016	0.00216	CcSEcCtD
Crizotinib—PTK2—female reproductive system—uterine cancer	0.00016	0.00159	CbGeAlD
Crizotinib—TBK1—female reproductive system—uterine cancer	0.00016	0.00159	CbGeAlD
Crizotinib—STK10—renal system—uterine cancer	0.000159	0.00159	CbGeAlD
Crizotinib—TYK2—female reproductive system—uterine cancer	0.000158	0.00158	CbGeAlD
Crizotinib—TAOK3—renal system—uterine cancer	0.000158	0.00158	CbGeAlD
Crizotinib—PTK2B—female gonad—uterine cancer	0.000158	0.00158	CbGeAlD
Crizotinib—Eye disorder—Etoposide—uterine cancer	0.000157	0.00212	CcSEcCtD
Crizotinib—SRC—decidua—uterine cancer	0.000157	0.00157	CbGeAlD
Crizotinib—PTK2B—vagina—uterine cancer	0.000157	0.00157	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000157	0.00211	CcSEcCtD
Crizotinib—IRAK1—female reproductive system—uterine cancer	0.000156	0.00156	CbGeAlD
Crizotinib—RIPK2—female gonad—uterine cancer	0.000156	0.00156	CbGeAlD
Crizotinib—Cardiac disorder—Etoposide—uterine cancer	0.000156	0.00211	CcSEcCtD
Crizotinib—Hepatic function abnormal—Epirubicin—uterine cancer	0.000156	0.0021	CcSEcCtD
Crizotinib—RIPK2—vagina—uterine cancer	0.000155	0.00155	CbGeAlD
Crizotinib—EPHB6—mammalian vulva—uterine cancer	0.000155	0.00155	CbGeAlD
Crizotinib—YES1—endometrium—uterine cancer	0.000155	0.00155	CbGeAlD
Crizotinib—CDK7—lymph node—uterine cancer	0.000155	0.00155	CbGeAlD
Crizotinib—TEK—uterus—uterine cancer	0.000155	0.00155	CbGeAlD
Crizotinib—MAP4K5—uterus—uterine cancer	0.000155	0.00155	CbGeAlD
Crizotinib—Dizziness—Progesterone—uterine cancer	0.000154	0.00208	CcSEcCtD
Crizotinib—SRC—renal system—uterine cancer	0.000154	0.00154	CbGeAlD
Crizotinib—TAOK2—lymph node—uterine cancer	0.000154	0.00153	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—uterine cancer	0.000153	0.00153	CbGeAlD
Crizotinib—TAOK3—endometrium—uterine cancer	0.000153	0.00153	CbGeAlD
Crizotinib—FGR—female reproductive system—uterine cancer	0.000153	0.00152	CbGeAlD
Crizotinib—AXL—female reproductive system—uterine cancer	0.000152	0.00152	CbGeAlD
Crizotinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000152	0.00205	CcSEcCtD
Crizotinib—Hepatic failure—Epirubicin—uterine cancer	0.000151	0.00205	CcSEcCtD
Crizotinib—Mediastinal disorder—Etoposide—uterine cancer	0.000151	0.00205	CcSEcCtD
Crizotinib—EPHA4—female gonad—uterine cancer	0.000151	0.00151	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—uterine cancer	0.000151	0.0533	CbGdCrCtD
Crizotinib—Sepsis—Doxorubicin—uterine cancer	0.000151	0.00203	CcSEcCtD
Crizotinib—ABL1—myometrium—uterine cancer	0.00015	0.0015	CbGeAlD
Crizotinib—EPHA4—vagina—uterine cancer	0.00015	0.0015	CbGeAlD
Crizotinib—YES1—mammalian vulva—uterine cancer	0.00015	0.0015	CbGeAlD
Crizotinib—STK10—mammalian vulva—uterine cancer	0.000148	0.00148	CbGeAlD
Crizotinib—Vomiting—Progesterone—uterine cancer	0.000148	0.002	CcSEcCtD
Crizotinib—MAP3K2—female gonad—uterine cancer	0.000148	0.00148	CbGeAlD
Crizotinib—TAOK3—mammalian vulva—uterine cancer	0.000148	0.00148	CbGeAlD
Crizotinib—CSF1R—uterine cervix—uterine cancer	0.000148	0.00148	CbGeAlD
Crizotinib—ACVR1B—lymph node—uterine cancer	0.000148	0.00148	CbGeAlD
Crizotinib—EPHA3—lymph node—uterine cancer	0.000148	0.00148	CbGeAlD
Crizotinib—Rash—Progesterone—uterine cancer	0.000147	0.00199	CcSEcCtD
Crizotinib—Dermatitis—Progesterone—uterine cancer	0.000147	0.00199	CcSEcCtD
Crizotinib—EPHB4—female reproductive system—uterine cancer	0.000145	0.00145	CbGeAlD
Crizotinib—PTK2—female gonad—uterine cancer	0.000145	0.00145	CbGeAlD
Crizotinib—TBK1—female gonad—uterine cancer	0.000145	0.00145	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000145	0.00196	CcSEcCtD
Crizotinib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000145	0.00195	CcSEcCtD
Crizotinib—TBK1—vagina—uterine cancer	0.000144	0.00144	CbGeAlD
Crizotinib—PTK2—vagina—uterine cancer	0.000144	0.00144	CbGeAlD
Crizotinib—TYK2—female gonad—uterine cancer	0.000144	0.00144	CbGeAlD
Crizotinib—JAK2—female reproductive system—uterine cancer	0.000144	0.00144	CbGeAlD
Crizotinib—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000144	0.00195	CcSEcCtD
Crizotinib—CSF1R—smooth muscle tissue—uterine cancer	0.000144	0.00144	CbGeAlD
Crizotinib—Decreased appetite—Dactinomycin—uterine cancer	0.000143	0.00194	CcSEcCtD
Crizotinib—TYK2—vagina—uterine cancer	0.000143	0.00143	CbGeAlD
Crizotinib—Dysgeusia—Etoposide—uterine cancer	0.000143	0.00193	CcSEcCtD
Crizotinib—YES1—uterus—uterine cancer	0.000143	0.00143	CbGeAlD
Crizotinib—EPHA2—female reproductive system—uterine cancer	0.000142	0.00142	CbGeAlD
Crizotinib—IRAK1—female gonad—uterine cancer	0.000142	0.00142	CbGeAlD
Crizotinib—Fatigue—Dactinomycin—uterine cancer	0.000142	0.00192	CcSEcCtD
Crizotinib—STK10—uterus—uterine cancer	0.000141	0.00141	CbGeAlD
Crizotinib—JAK3—lymph node—uterine cancer	0.000141	0.00141	CbGeAlD
Crizotinib—CSF1R—decidua—uterine cancer	0.000141	0.00141	CbGeAlD
Crizotinib—TAOK3—uterus—uterine cancer	0.000141	0.00141	CbGeAlD
Crizotinib—DCLK1—lymph node—uterine cancer	0.00014	0.0014	CbGeAlD
Crizotinib—Hepatic failure—Doxorubicin—uterine cancer	0.00014	0.00189	CcSEcCtD
Crizotinib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00014	0.00189	CcSEcCtD
Crizotinib—RPS6KB1—female gonad—uterine cancer	0.00014	0.0014	CbGeAlD
Crizotinib—PLK4—lymph node—uterine cancer	0.000139	0.00139	CbGeAlD
Crizotinib—MAP4K5—female reproductive system—uterine cancer	0.000139	0.00139	CbGeAlD
Crizotinib—MAP3K3—female reproductive system—uterine cancer	0.000139	0.00139	CbGeAlD
Crizotinib—TEK—female reproductive system—uterine cancer	0.000139	0.00139	CbGeAlD
Crizotinib—RPS6KB1—vagina—uterine cancer	0.000139	0.00139	CbGeAlD
Crizotinib—LCK—female gonad—uterine cancer	0.000139	0.00139	CbGeAlD
Crizotinib—FGR—female gonad—uterine cancer	0.000139	0.00139	CbGeAlD
Crizotinib—Nausea—Progesterone—uterine cancer	0.000139	0.00187	CcSEcCtD
Crizotinib—STK4—lymph node—uterine cancer	0.000138	0.00138	CbGeAlD
Crizotinib—AXL—female gonad—uterine cancer	0.000138	0.00138	CbGeAlD
Crizotinib—FGR—vagina—uterine cancer	0.000138	0.00138	CbGeAlD
Crizotinib—LCK—vagina—uterine cancer	0.000138	0.00138	CbGeAlD
Crizotinib—AXL—vagina—uterine cancer	0.000137	0.00137	CbGeAlD
Crizotinib—Diplopia—Epirubicin—uterine cancer	0.000136	0.00184	CcSEcCtD
Crizotinib—Anaemia—Etoposide—uterine cancer	0.000135	0.00183	CcSEcCtD
Crizotinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000134	0.00182	CcSEcCtD
Crizotinib—CSF1R—endometrium—uterine cancer	0.000134	0.00134	CbGeAlD
Crizotinib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000133	0.0018	CcSEcCtD
Crizotinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000133	0.0018	CcSEcCtD
Crizotinib—SLK—female gonad—uterine cancer	0.000133	0.00133	CbGeAlD
Crizotinib—SLK—vagina—uterine cancer	0.000132	0.00132	CbGeAlD
Crizotinib—EPHB4—female gonad—uterine cancer	0.000132	0.00132	CbGeAlD
Crizotinib—CDK7—Doxorubicin—Epirubicin—uterine cancer	0.000132	0.0464	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—uterine cancer	0.000132	0.0464	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—uterine cancer	0.000132	0.0464	CbGdCrCtD
Crizotinib—Face oedema—Epirubicin—uterine cancer	0.000131	0.00178	CcSEcCtD
Crizotinib—EPHB4—vagina—uterine cancer	0.000131	0.00131	CbGeAlD
Crizotinib—JAK2—female gonad—uterine cancer	0.000131	0.00131	CbGeAlD
Crizotinib—Leukopenia—Etoposide—uterine cancer	0.000131	0.00177	CcSEcCtD
Crizotinib—ALK—lymph node—uterine cancer	0.000131	0.00131	CbGeAlD
Crizotinib—FER—lymph node—uterine cancer	0.000131	0.00131	CbGeAlD
Crizotinib—JAK2—vagina—uterine cancer	0.00013	0.0013	CbGeAlD
Crizotinib—Body temperature increased—Dactinomycin—uterine cancer	0.00013	0.00176	CcSEcCtD
Crizotinib—EPHA2—female gonad—uterine cancer	0.00013	0.0013	CbGeAlD
Crizotinib—TNK1—lymph node—uterine cancer	0.00013	0.00129	CbGeAlD
Crizotinib—CSF1R—mammalian vulva—uterine cancer	0.000129	0.00129	CbGeAlD
Crizotinib—EPHA2—vagina—uterine cancer	0.000129	0.00129	CbGeAlD
Crizotinib—AURKA—Teniposide—Etoposide—uterine cancer	0.000129	0.0454	CbGdCrCtD
Crizotinib—Loss of consciousness—Etoposide—uterine cancer	0.000129	0.00174	CcSEcCtD
Crizotinib—YES1—female reproductive system—uterine cancer	0.000128	0.00128	CbGeAlD
Crizotinib—BMPR1B—lymph node—uterine cancer	0.000128	0.00128	CbGeAlD
Crizotinib—MAP4K1—lymph node—uterine cancer	0.000128	0.00128	CbGeAlD
Crizotinib—STK10—female reproductive system—uterine cancer	0.000127	0.00127	CbGeAlD
Crizotinib—TAOK3—female reproductive system—uterine cancer	0.000127	0.00127	CbGeAlD
Crizotinib—MAP4K5—female gonad—uterine cancer	0.000126	0.00126	CbGeAlD
Crizotinib—MAP3K3—female gonad—uterine cancer	0.000126	0.00126	CbGeAlD
Crizotinib—TEK—female gonad—uterine cancer	0.000126	0.00126	CbGeAlD
Crizotinib—Diplopia—Doxorubicin—uterine cancer	0.000126	0.0017	CcSEcCtD
Crizotinib—TNK2—lymph node—uterine cancer	0.000126	0.00126	CbGeAlD
Crizotinib—IGF1R—lymph node—uterine cancer	0.000126	0.00126	CbGeAlD
Crizotinib—MAP4K5—vagina—uterine cancer	0.000126	0.00126	CbGeAlD
Crizotinib—MAP3K3—vagina—uterine cancer	0.000126	0.00126	CbGeAlD
Crizotinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000126	0.0017	CcSEcCtD
Crizotinib—MAP4K2—lymph node—uterine cancer	0.000124	0.00124	CbGeAlD
Crizotinib—Hypokalaemia—Epirubicin—uterine cancer	0.000124	0.00167	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000124	0.00167	CcSEcCtD
Crizotinib—SRC—female reproductive system—uterine cancer	0.000123	0.00123	CbGeAlD
Crizotinib—CSF1R—uterus—uterine cancer	0.000123	0.00123	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000123	0.00166	CcSEcCtD
Crizotinib—STK3—lymph node—uterine cancer	0.000122	0.00122	CbGeAlD
Crizotinib—TIE1—lymph node—uterine cancer	0.000122	0.00122	CbGeAlD
Crizotinib—CDK7—Epirubicin—Doxorubicin—uterine cancer	0.000122	0.0429	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—uterine cancer	0.000122	0.0429	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—uterine cancer	0.000122	0.0429	CbGdCrCtD
Crizotinib—Face oedema—Doxorubicin—uterine cancer	0.000122	0.00164	CcSEcCtD
Crizotinib—EPHB6—female gonad—uterine cancer	0.000121	0.00121	CbGeAlD
Crizotinib—EPHB6—vagina—uterine cancer	0.00012	0.0012	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.00012	0.00162	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—uterine cancer	0.00012	0.00162	CcSEcCtD
Crizotinib—AURKA—lymph node—uterine cancer	0.000119	0.00119	CbGeAlD
Crizotinib—Infection—Etoposide—uterine cancer	0.000119	0.0016	CcSEcCtD
Crizotinib—Asthenia—Dactinomycin—uterine cancer	0.000118	0.0016	CcSEcCtD
Crizotinib—TESK1—lymph node—uterine cancer	0.000118	0.00118	CbGeAlD
Crizotinib—ABL1—uterine cervix—uterine cancer	0.000117	0.00117	CbGeAlD
Crizotinib—YES1—female gonad—uterine cancer	0.000117	0.00117	CbGeAlD
Crizotinib—YES1—vagina—uterine cancer	0.000116	0.00116	CbGeAlD
Crizotinib—Skin disorder—Etoposide—uterine cancer	0.000116	0.00157	CcSEcCtD
Crizotinib—STK10—female gonad—uterine cancer	0.000116	0.00116	CbGeAlD
Crizotinib—TAOK3—female gonad—uterine cancer	0.000115	0.00115	CbGeAlD
Crizotinib—STK10—vagina—uterine cancer	0.000115	0.00115	CbGeAlD
Crizotinib—MERTK—lymph node—uterine cancer	0.000115	0.00115	CbGeAlD
Crizotinib—Hypokalaemia—Doxorubicin—uterine cancer	0.000115	0.00155	CcSEcCtD
Crizotinib—TAOK3—vagina—uterine cancer	0.000115	0.00115	CbGeAlD
Crizotinib—ABL1—smooth muscle tissue—uterine cancer	0.000114	0.00114	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000113	0.00153	CcSEcCtD
Crizotinib—Diarrhoea—Dactinomycin—uterine cancer	0.000113	0.00152	CcSEcCtD
Crizotinib—LIMK2—lymph node—uterine cancer	0.000112	0.00112	CbGeAlD
Crizotinib—SRC—female gonad—uterine cancer	0.000112	0.00112	CbGeAlD
Crizotinib—NUAK2—lymph node—uterine cancer	0.000112	0.00112	CbGeAlD
Crizotinib—ABL1—decidua—uterine cancer	0.000111	0.00111	CbGeAlD
Crizotinib—MAP3K12—lymph node—uterine cancer	0.000111	0.00111	CbGeAlD
Crizotinib—ACVR1—lymph node—uterine cancer	0.000111	0.00111	CbGeAlD
Crizotinib—FLT3—lymph node—uterine cancer	0.000111	0.00111	CbGeAlD
Crizotinib—Muscular weakness—Doxorubicin—uterine cancer	0.000111	0.0015	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000111	0.0015	CcSEcCtD
Crizotinib—CSF1R—female reproductive system—uterine cancer	0.000111	0.00111	CbGeAlD
Crizotinib—Neutropenia—Epirubicin—uterine cancer	0.00011	0.00149	CcSEcCtD
Crizotinib—ABL1—renal system—uterine cancer	0.000109	0.00109	CbGeAlD
Crizotinib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000109	0.00148	CcSEcCtD
Crizotinib—STK35—lymph node—uterine cancer	0.000109	0.00109	CbGeAlD
Crizotinib—Paraesthesia—Etoposide—uterine cancer	0.000107	0.00145	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—uterine cancer	0.000106	0.00144	CcSEcCtD
Crizotinib—Dyspnoea—Etoposide—uterine cancer	0.000106	0.00144	CcSEcCtD
Crizotinib—ABL2—lymph node—uterine cancer	0.000106	0.00106	CbGeAlD
Crizotinib—ABL1—endometrium—uterine cancer	0.000106	0.00106	CbGeAlD
Crizotinib—Pneumonia—Epirubicin—uterine cancer	0.000106	0.00143	CcSEcCtD
Crizotinib—BMP2K—lymph node—uterine cancer	0.000105	0.00105	CbGeAlD
Crizotinib—Infestation—Epirubicin—uterine cancer	0.000105	0.00142	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—uterine cancer	0.000105	0.00142	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—uterine cancer	0.000105	0.00142	CcSEcCtD
Crizotinib—Rash—Dactinomycin—uterine cancer	0.000104	0.0014	CcSEcCtD
Crizotinib—Decreased appetite—Etoposide—uterine cancer	0.000104	0.0014	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000103	0.00139	CcSEcCtD
Crizotinib—Fatigue—Etoposide—uterine cancer	0.000103	0.00139	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—uterine cancer	0.000103	0.00139	CcSEcCtD
Crizotinib—ABL1—mammalian vulva—uterine cancer	0.000102	0.00102	CbGeAlD
Crizotinib—Constipation—Etoposide—uterine cancer	0.000102	0.00138	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—uterine cancer	0.000102	0.00138	CcSEcCtD
Crizotinib—PTK2B—lymph node—uterine cancer	0.000101	0.00101	CbGeAlD
Crizotinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000101	0.00137	CcSEcCtD
Crizotinib—CSF1R—female gonad—uterine cancer	0.000101	0.00101	CbGeAlD
Crizotinib—RIPK2—lymph node—uterine cancer	0.000101	0.001	CbGeAlD
Crizotinib—CSF1R—vagina—uterine cancer	0.0001	0.001	CbGeAlD
Crizotinib—Hepatobiliary disease—Epirubicin—uterine cancer	9.92e-05	0.00134	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—uterine cancer	9.85e-05	0.00133	CcSEcCtD
Crizotinib—Nausea—Dactinomycin—uterine cancer	9.8e-05	0.00132	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—uterine cancer	9.76e-05	0.00132	CcSEcCtD
Crizotinib—ABL1—uterus—uterine cancer	9.74e-05	0.000974	CbGeAlD
Crizotinib—EPHA4—lymph node—uterine cancer	9.72e-05	0.000971	CbGeAlD
Crizotinib—Infestation—Doxorubicin—uterine cancer	9.71e-05	0.00131	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—uterine cancer	9.71e-05	0.00131	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—uterine cancer	9.59e-05	0.0013	CcSEcCtD
Crizotinib—MAP3K2—lymph node—uterine cancer	9.53e-05	0.000953	CbGeAlD
Crizotinib—Neuropathy peripheral—Doxorubicin—uterine cancer	9.52e-05	0.00129	CcSEcCtD
Crizotinib—Body temperature increased—Etoposide—uterine cancer	9.44e-05	0.00127	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—uterine cancer	9.37e-05	0.00127	CcSEcCtD
Crizotinib—PTK2—lymph node—uterine cancer	9.33e-05	0.000933	CbGeAlD
Crizotinib—TBK1—lymph node—uterine cancer	9.33e-05	0.000933	CbGeAlD
Crizotinib—Urinary tract disorder—Epirubicin—uterine cancer	9.3e-05	0.00126	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—uterine cancer	9.28e-05	0.00125	CcSEcCtD
Crizotinib—TYK2—lymph node—uterine cancer	9.27e-05	0.000927	CbGeAlD
Crizotinib—Urethral disorder—Epirubicin—uterine cancer	9.23e-05	0.00125	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—uterine cancer	9.18e-05	0.00124	CcSEcCtD
Crizotinib—IRAK1—lymph node—uterine cancer	9.15e-05	0.000915	CbGeAlD
Crizotinib—Visual impairment—Epirubicin—uterine cancer	9.08e-05	0.00123	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—uterine cancer	8.98e-05	0.000898	CbGeAlD
Crizotinib—FGR—lymph node—uterine cancer	8.92e-05	0.000892	CbGeAlD
Crizotinib—LCK—lymph node—uterine cancer	8.92e-05	0.000892	CbGeAlD
Crizotinib—AXL—lymph node—uterine cancer	8.89e-05	0.000888	CbGeAlD
Crizotinib—Bradycardia—Doxorubicin—uterine cancer	8.87e-05	0.0012	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—uterine cancer	8.8e-05	0.00119	CcSEcCtD
Crizotinib—ABL1—female reproductive system—uterine cancer	8.76e-05	0.000876	CbGeAlD
Crizotinib—Cardiac disorder—Epirubicin—uterine cancer	8.74e-05	0.00118	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—uterine cancer	8.67e-05	0.00117	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—uterine cancer	8.61e-05	0.00116	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—uterine cancer	8.58e-05	0.00116	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—uterine cancer	8.58e-05	0.0302	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—uterine cancer	8.58e-05	0.0302	CbGdCrCtD
Crizotinib—Asthenia—Etoposide—uterine cancer	8.56e-05	0.00116	CcSEcCtD
Crizotinib—SLK—lymph node—uterine cancer	8.55e-05	0.000855	CbGeAlD
Crizotinib—Urethral disorder—Doxorubicin—uterine cancer	8.54e-05	0.00115	CcSEcCtD
Crizotinib—EPHB4—lymph node—uterine cancer	8.49e-05	0.000849	CbGeAlD
Crizotinib—Mediastinal disorder—Epirubicin—uterine cancer	8.49e-05	0.00115	CcSEcCtD
Crizotinib—JAK2—lymph node—uterine cancer	8.43e-05	0.000843	CbGeAlD
Crizotinib—Arrhythmia—Epirubicin—uterine cancer	8.41e-05	0.00114	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—uterine cancer	8.4e-05	0.00113	CcSEcCtD
Crizotinib—EPHA2—lymph node—uterine cancer	8.33e-05	0.000833	CbGeAlD
Crizotinib—Malnutrition—Epirubicin—uterine cancer	8.2e-05	0.00111	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—uterine cancer	8.17e-05	0.0011	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—uterine cancer	8.14e-05	0.0011	CcSEcCtD
Crizotinib—TEK—lymph node—uterine cancer	8.13e-05	0.000813	CbGeAlD
Crizotinib—MAP3K3—lymph node—uterine cancer	8.13e-05	0.000813	CbGeAlD
Crizotinib—MAP4K5—lymph node—uterine cancer	8.13e-05	0.000813	CbGeAlD
Crizotinib—Cardiac disorder—Doxorubicin—uterine cancer	8.09e-05	0.00109	CcSEcCtD
Crizotinib—Dysgeusia—Epirubicin—uterine cancer	8.03e-05	0.00108	CcSEcCtD
Crizotinib—ABL1—female gonad—uterine cancer	7.97e-05	0.000797	CbGeAlD
Crizotinib—PLK4—Idarubicin—Doxorubicin—uterine cancer	7.94e-05	0.028	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—uterine cancer	7.94e-05	0.028	CbGdCrCtD
Crizotinib—ABL1—vagina—uterine cancer	7.92e-05	0.000792	CbGeAlD
Crizotinib—Dizziness—Etoposide—uterine cancer	7.89e-05	0.00107	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—uterine cancer	7.85e-05	0.00106	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—uterine cancer	7.78e-05	0.00105	CcSEcCtD
Crizotinib—EPHB6—lymph node—uterine cancer	7.77e-05	0.000777	CbGeAlD
Crizotinib—Vision blurred—Epirubicin—uterine cancer	7.73e-05	0.00104	CcSEcCtD
Crizotinib—Vomiting—Etoposide—uterine cancer	7.59e-05	0.00103	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—uterine cancer	7.59e-05	0.00102	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—uterine cancer	7.58e-05	0.00102	CcSEcCtD
Crizotinib—Rash—Etoposide—uterine cancer	7.53e-05	0.00102	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—uterine cancer	7.52e-05	0.00102	CcSEcCtD
Crizotinib—YES1—lymph node—uterine cancer	7.51e-05	0.00075	CbGeAlD
Crizotinib—STK10—lymph node—uterine cancer	7.44e-05	0.000744	CbGeAlD
Crizotinib—Dysgeusia—Doxorubicin—uterine cancer	7.43e-05	0.001	CcSEcCtD
Crizotinib—TAOK3—lymph node—uterine cancer	7.41e-05	0.000741	CbGeAlD
Crizotinib—Syncope—Epirubicin—uterine cancer	7.35e-05	0.000993	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—uterine cancer	7.34e-05	0.000991	CcSEcCtD
Crizotinib—SRC—lymph node—uterine cancer	7.22e-05	0.000722	CbGeAlD
Crizotinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	7.21e-05	0.0254	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	7.21e-05	0.0254	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—uterine cancer	7.21e-05	0.0254	CbGdCrCtD
Crizotinib—Loss of consciousness—Epirubicin—uterine cancer	7.21e-05	0.000973	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—uterine cancer	7.15e-05	0.000966	CcSEcCtD
Crizotinib—Nausea—Etoposide—uterine cancer	7.09e-05	0.000958	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—uterine cancer	7.01e-05	0.000947	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.93e-05	0.000936	CcSEcCtD
Crizotinib—CYP3A5—uterine cervix—uterine cancer	6.84e-05	0.000684	CbGeAlD
Crizotinib—Syncope—Doxorubicin—uterine cancer	6.8e-05	0.000919	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—uterine cancer	6.79e-05	0.000917	CcSEcCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—uterine cancer	6.72e-05	0.0237	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—uterine cancer	6.72e-05	0.0237	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—uterine cancer	6.72e-05	0.0237	CbGdCrCtD
Crizotinib—Oedema—Epirubicin—uterine cancer	6.69e-05	0.000904	CcSEcCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	6.67e-05	0.0235	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	6.67e-05	0.0235	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	6.67e-05	0.0235	CbGdCrCtD
Crizotinib—Loss of consciousness—Doxorubicin—uterine cancer	6.67e-05	0.000901	CcSEcCtD
Crizotinib—Infection—Epirubicin—uterine cancer	6.65e-05	0.000898	CcSEcCtD
Crizotinib—Shock—Epirubicin—uterine cancer	6.58e-05	0.000889	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—uterine cancer	6.56e-05	0.000886	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—uterine cancer	6.5e-05	0.000878	CcSEcCtD
Crizotinib—CSF1R—lymph node—uterine cancer	6.48e-05	0.000648	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.41e-05	0.000866	CcSEcCtD
Crizotinib—CYP3A5—renal system—uterine cancer	6.4e-05	0.00064	CbGeAlD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—uterine cancer	6.21e-05	0.0219	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—uterine cancer	6.21e-05	0.0219	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—uterine cancer	6.21e-05	0.0219	CbGdCrCtD
Crizotinib—Oedema—Doxorubicin—uterine cancer	6.19e-05	0.000836	CcSEcCtD
Crizotinib—Infection—Doxorubicin—uterine cancer	6.15e-05	0.000831	CcSEcCtD
Crizotinib—Shock—Doxorubicin—uterine cancer	6.09e-05	0.000823	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—uterine cancer	6.07e-05	0.00082	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—uterine cancer	6.01e-05	0.000812	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—uterine cancer	6.01e-05	0.000812	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—uterine cancer	5.97e-05	0.000806	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—uterine cancer	5.89e-05	0.000796	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—uterine cancer	5.82e-05	0.000786	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—uterine cancer	5.78e-05	0.00078	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—uterine cancer	5.77e-05	0.000779	CcSEcCtD
Crizotinib—Constipation—Epirubicin—uterine cancer	5.72e-05	0.000773	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—uterine cancer	5.56e-05	0.000751	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—uterine cancer	5.52e-05	0.000746	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—uterine cancer	5.45e-05	0.000736	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—uterine cancer	5.38e-05	0.000727	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.34e-05	0.000722	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—uterine cancer	5.34e-05	0.000721	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—uterine cancer	5.29e-05	0.000715	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—uterine cancer	5.29e-05	0.000715	CcSEcCtD
Crizotinib—ABL1—lymph node—uterine cancer	5.12e-05	0.000512	CbGeAlD
Crizotinib—Body temperature increased—Doxorubicin—uterine cancer	4.89e-05	0.000661	CcSEcCtD
Crizotinib—CYP3A4—renal system—uterine cancer	4.81e-05	0.00048	CbGeAlD
Crizotinib—Asthenia—Epirubicin—uterine cancer	4.8e-05	0.000649	CcSEcCtD
Crizotinib—ABCB1—myometrium—uterine cancer	4.67e-05	0.000467	CbGeAlD
Crizotinib—CYP3A5—female gonad—uterine cancer	4.67e-05	0.000467	CbGeAlD
Crizotinib—CYP3A5—vagina—uterine cancer	4.64e-05	0.000464	CbGeAlD
Crizotinib—Diarrhoea—Epirubicin—uterine cancer	4.58e-05	0.000618	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—uterine cancer	4.44e-05	0.0006	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—uterine cancer	4.42e-05	0.000598	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—uterine cancer	4.25e-05	0.000575	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—uterine cancer	4.24e-05	0.000572	CcSEcCtD
Crizotinib—Rash—Epirubicin—uterine cancer	4.22e-05	0.00057	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—uterine cancer	4.21e-05	0.000569	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—uterine cancer	4.09e-05	0.000553	CcSEcCtD
Crizotinib—Nausea—Epirubicin—uterine cancer	3.97e-05	0.000537	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—uterine cancer	3.94e-05	0.000532	CcSEcCtD
Crizotinib—Rash—Doxorubicin—uterine cancer	3.9e-05	0.000527	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—uterine cancer	3.9e-05	0.000527	CcSEcCtD
Crizotinib—CYP3A4—female reproductive system—uterine cancer	3.85e-05	0.000385	CbGeAlD
Crizotinib—Nausea—Doxorubicin—uterine cancer	3.68e-05	0.000497	CcSEcCtD
Crizotinib—ABCB1—epithelium—uterine cancer	3.67e-05	0.000367	CbGeAlD
Crizotinib—ABCB1—uterine cervix—uterine cancer	3.64e-05	0.000363	CbGeAlD
Crizotinib—ABCB1—decidua—uterine cancer	3.46e-05	0.000346	CbGeAlD
Crizotinib—ABCB1—renal system—uterine cancer	3.4e-05	0.00034	CbGeAlD
Crizotinib—ABCB1—endometrium—uterine cancer	3.29e-05	0.000329	CbGeAlD
Crizotinib—ABCB1—mammalian vulva—uterine cancer	3.18e-05	0.000318	CbGeAlD
Crizotinib—ABCB1—uterus—uterine cancer	3.03e-05	0.000303	CbGeAlD
Crizotinib—ABCB1—female reproductive system—uterine cancer	2.72e-05	0.000272	CbGeAlD
Crizotinib—ABCB1—female gonad—uterine cancer	2.48e-05	0.000248	CbGeAlD
Crizotinib—ABCB1—vagina—uterine cancer	2.46e-05	0.000246	CbGeAlD
Crizotinib—ABCB1—lymph node—uterine cancer	1.59e-05	0.000159	CbGeAlD
Crizotinib—JAK2—Signaling by GPCR—NRAS—uterine cancer	1.33e-06	1.02e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—uterine cancer	1.32e-06	1.01e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—uterine cancer	1.31e-06	1.01e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CTNNB1—uterine cancer	1.31e-06	1e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—uterine cancer	1.31e-06	1e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—PIK3CA—uterine cancer	1.31e-06	1e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1B—uterine cancer	1.3e-06	9.95e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—uterine cancer	1.3e-06	9.94e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—uterine cancer	1.3e-06	9.94e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1B—uterine cancer	1.3e-06	9.92e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CTNNB1—uterine cancer	1.29e-06	9.91e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—uterine cancer	1.29e-06	9.89e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CXCL8—uterine cancer	1.29e-06	9.89e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—uterine cancer	1.29e-06	9.89e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—uterine cancer	1.29e-06	9.89e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PIK3CA—uterine cancer	1.29e-06	9.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CTNNB1—uterine cancer	1.29e-06	9.88e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—uterine cancer	1.28e-06	9.83e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—uterine cancer	1.28e-06	9.83e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PTEN—uterine cancer	1.28e-06	9.8e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—PIK3CA—uterine cancer	1.28e-06	9.79e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR2—uterine cancer	1.27e-06	9.76e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—uterine cancer	1.27e-06	9.75e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—uterine cancer	1.27e-06	9.75e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POLD1—uterine cancer	1.27e-06	9.72e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—PIK3CA—uterine cancer	1.27e-06	9.7e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PTEN—uterine cancer	1.26e-06	9.66e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1B—uterine cancer	1.26e-06	9.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTEN—uterine cancer	1.26e-06	9.63e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—uterine cancer	1.25e-06	9.59e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—uterine cancer	1.25e-06	9.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—uterine cancer	1.24e-06	9.48e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—uterine cancer	1.24e-06	9.48e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—uterine cancer	1.23e-06	9.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ESR1—uterine cancer	1.23e-06	9.43e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—PIK3CA—uterine cancer	1.23e-06	9.4e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CTNNB1—uterine cancer	1.23e-06	9.4e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTNNB1—uterine cancer	1.22e-06	9.37e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—uterine cancer	1.22e-06	9.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—uterine cancer	1.21e-06	9.3e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—uterine cancer	1.21e-06	9.25e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—uterine cancer	1.2e-06	9.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—uterine cancer	1.2e-06	9.18e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTEN—uterine cancer	1.2e-06	9.16e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1B—uterine cancer	1.2e-06	9.16e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—uterine cancer	1.19e-06	9.14e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PTEN—uterine cancer	1.19e-06	9.13e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CTNNB1—uterine cancer	1.19e-06	9.13e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.19e-06	9.09e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—uterine cancer	1.18e-06	9.06e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—uterine cancer	1.18e-06	9.06e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—uterine cancer	1.18e-06	9.04e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—uterine cancer	1.18e-06	9.04e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—uterine cancer	1.17e-06	8.98e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—PIK3CA—uterine cancer	1.17e-06	8.96e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTEN—uterine cancer	1.16e-06	8.89e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—uterine cancer	1.16e-06	8.88e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—PIK3CA—uterine cancer	1.16e-06	8.86e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—uterine cancer	1.16e-06	8.85e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—STK11—uterine cancer	1.16e-06	8.85e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP19A1—uterine cancer	1.16e-06	8.85e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—uterine cancer	1.15e-06	8.81e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PIK3CA—uterine cancer	1.15e-06	8.81e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1B—uterine cancer	1.15e-06	8.78e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—uterine cancer	1.14e-06	8.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—uterine cancer	1.14e-06	8.76e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—uterine cancer	1.14e-06	8.75e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—uterine cancer	1.14e-06	8.74e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—uterine cancer	1.14e-06	8.74e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—uterine cancer	1.14e-06	8.73e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—uterine cancer	1.14e-06	8.73e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—uterine cancer	1.14e-06	8.71e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—uterine cancer	1.14e-06	8.7e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PIK3CA—uterine cancer	1.13e-06	8.68e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—uterine cancer	1.13e-06	8.68e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—uterine cancer	1.13e-06	8.68e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CTNNB1—uterine cancer	1.13e-06	8.65e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—uterine cancer	1.13e-06	8.62e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—uterine cancer	1.12e-06	8.61e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—uterine cancer	1.12e-06	8.59e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—uterine cancer	1.12e-06	8.55e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—uterine cancer	1.11e-06	8.52e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—uterine cancer	1.11e-06	8.51e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—uterine cancer	1.11e-06	8.48e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—uterine cancer	1.1e-06	8.45e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTEN—uterine cancer	1.1e-06	8.43e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—uterine cancer	1.1e-06	8.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ESR1—uterine cancer	1.09e-06	8.35e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—uterine cancer	1.08e-06	8.31e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—uterine cancer	1.08e-06	8.3e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTNNB1—uterine cancer	1.08e-06	8.29e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—uterine cancer	1.08e-06	8.29e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—uterine cancer	1.08e-06	8.28e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—uterine cancer	1.07e-06	8.17e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—uterine cancer	1.07e-06	8.17e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—uterine cancer	1.06e-06	8.15e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—uterine cancer	1.06e-06	8.15e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1B—uterine cancer	1.06e-06	8.11e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RRM2—uterine cancer	1.06e-06	8.1e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTEN—uterine cancer	1.06e-06	8.08e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—uterine cancer	1.05e-06	8.07e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—uterine cancer	1.05e-06	8.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—uterine cancer	1.05e-06	8.05e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—uterine cancer	1.05e-06	8.04e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—uterine cancer	1.05e-06	8.04e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—uterine cancer	1.05e-06	8.03e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—uterine cancer	1.05e-06	8.03e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—uterine cancer	1.05e-06	8.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—uterine cancer	1.05e-06	8.01e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—uterine cancer	1.04e-06	8e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—uterine cancer	1.04e-06	7.94e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—uterine cancer	1.04e-06	7.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—uterine cancer	1.03e-06	7.9e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DCN—uterine cancer	1.03e-06	7.86e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—uterine cancer	1.03e-06	7.86e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—uterine cancer	1.02e-06	7.82e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—uterine cancer	1.02e-06	7.82e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—uterine cancer	1.02e-06	7.79e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—uterine cancer	1.01e-06	7.71e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—uterine cancer	1e-06	7.68e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—uterine cancer	1e-06	7.68e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—uterine cancer	1e-06	7.66e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—uterine cancer	9.82e-07	7.52e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—uterine cancer	9.82e-07	7.52e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—uterine cancer	9.79e-07	7.5e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—uterine cancer	9.75e-07	7.46e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—uterine cancer	9.73e-07	7.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—uterine cancer	9.73e-07	7.45e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—uterine cancer	9.69e-07	7.42e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	9.67e-07	7.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—uterine cancer	9.65e-07	7.39e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—uterine cancer	9.65e-07	7.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—uterine cancer	9.6e-07	7.36e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—uterine cancer	9.6e-07	7.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—uterine cancer	9.56e-07	7.32e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—uterine cancer	9.56e-07	7.32e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—uterine cancer	9.5e-07	7.27e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—uterine cancer	9.46e-07	7.24e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—uterine cancer	9.45e-07	7.24e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—uterine cancer	9.42e-07	7.21e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—uterine cancer	9.41e-07	7.2e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—uterine cancer	9.39e-07	7.19e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—uterine cancer	9.3e-07	7.12e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—uterine cancer	9.26e-07	7.09e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—uterine cancer	9.19e-07	7.04e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—uterine cancer	9.16e-07	7.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	9.14e-07	7e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—uterine cancer	9.04e-07	6.92e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—uterine cancer	9.03e-07	6.92e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—uterine cancer	9.02e-07	6.91e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—uterine cancer	8.97e-07	6.87e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—uterine cancer	8.92e-07	6.83e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—uterine cancer	8.9e-07	6.81e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—uterine cancer	8.89e-07	6.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—uterine cancer	8.87e-07	6.79e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—uterine cancer	8.86e-07	6.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—uterine cancer	8.8e-07	6.74e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—uterine cancer	8.73e-07	6.68e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—uterine cancer	8.7e-07	6.66e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—uterine cancer	8.68e-07	6.65e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—uterine cancer	8.61e-07	6.59e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—uterine cancer	8.59e-07	6.58e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—uterine cancer	8.59e-07	6.58e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—uterine cancer	8.57e-07	6.57e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—uterine cancer	8.5e-07	6.51e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—uterine cancer	8.45e-07	6.47e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—uterine cancer	8.44e-07	6.46e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—uterine cancer	8.41e-07	6.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—uterine cancer	8.39e-07	6.43e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—uterine cancer	8.39e-07	6.43e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—uterine cancer	8.38e-07	6.42e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—uterine cancer	8.37e-07	6.41e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—uterine cancer	8.35e-07	6.39e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—uterine cancer	8.35e-07	6.39e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—uterine cancer	8.23e-07	6.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—uterine cancer	8.2e-07	6.28e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—uterine cancer	8.19e-07	6.27e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—uterine cancer	8.17e-07	6.25e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—uterine cancer	8.11e-07	6.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—uterine cancer	8e-07	6.13e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—uterine cancer	7.95e-07	6.09e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—uterine cancer	7.93e-07	6.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—uterine cancer	7.91e-07	6.06e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—uterine cancer	7.85e-07	6.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—uterine cancer	7.85e-07	6.01e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—uterine cancer	7.81e-07	5.98e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—uterine cancer	7.78e-07	5.96e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—uterine cancer	7.77e-07	5.95e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—uterine cancer	7.71e-07	5.9e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—uterine cancer	7.59e-07	5.81e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—uterine cancer	7.58e-07	5.81e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—uterine cancer	7.48e-07	5.73e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—uterine cancer	7.45e-07	5.7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—uterine cancer	7.41e-07	5.68e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—uterine cancer	7.37e-07	5.64e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—uterine cancer	7.35e-07	5.63e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—uterine cancer	7.27e-07	5.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—uterine cancer	7.24e-07	5.55e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—uterine cancer	7.22e-07	5.53e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—uterine cancer	7.19e-07	5.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—STK11—uterine cancer	7.12e-07	5.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	7.12e-07	5.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—uterine cancer	7e-07	5.36e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—uterine cancer	6.96e-07	5.33e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—uterine cancer	6.9e-07	5.28e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—uterine cancer	6.89e-07	5.28e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—uterine cancer	6.88e-07	5.27e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—uterine cancer	6.88e-07	5.27e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—uterine cancer	6.87e-07	5.26e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—uterine cancer	6.83e-07	5.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—uterine cancer	6.76e-07	5.18e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—uterine cancer	6.69e-07	5.13e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—uterine cancer	6.64e-07	5.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—uterine cancer	6.51e-07	4.98e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—uterine cancer	6.42e-07	4.92e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—uterine cancer	6.4e-07	4.9e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—uterine cancer	6.36e-07	4.87e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—uterine cancer	6.34e-07	4.86e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—uterine cancer	6.21e-07	4.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—uterine cancer	6.16e-07	4.72e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—uterine cancer	6.14e-07	4.7e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—uterine cancer	6.1e-07	4.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—uterine cancer	6.09e-07	4.66e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—uterine cancer	6.08e-07	4.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—uterine cancer	6.01e-07	4.6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—uterine cancer	5.92e-07	4.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—uterine cancer	5.75e-07	4.4e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—uterine cancer	5.62e-07	4.3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—uterine cancer	5.44e-07	4.17e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—uterine cancer	5.42e-07	4.15e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—uterine cancer	5.35e-07	4.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—uterine cancer	5.26e-07	4.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—uterine cancer	5.24e-07	4.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—uterine cancer	5.07e-07	3.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—uterine cancer	5.03e-07	3.85e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—uterine cancer	4.83e-07	3.7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—uterine cancer	4.82e-07	3.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—uterine cancer	4.66e-07	3.57e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—uterine cancer	4.61e-07	3.53e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—uterine cancer	4.51e-07	3.46e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—uterine cancer	4.45e-07	3.41e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—uterine cancer	4.44e-07	3.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—uterine cancer	3.93e-07	3.01e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—uterine cancer	3.69e-07	2.82e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—uterine cancer	3.41e-07	2.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—uterine cancer	2.98e-07	2.28e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—uterine cancer	2.84e-07	2.17e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—uterine cancer	2.78e-07	2.13e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.1e-07	1.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—uterine cancer	1.71e-07	1.31e-06	CbGpPWpGaD
